EDMONTON, May 27 /CNW/ - Isotechnika Inc. (TSX:ISA) today announced positive results from the Phase 2b PROMISE trial which evaluated the Company’s lead drug, voclosporin, in de novo kidney transplant patients. This trial was designed to determine the most appropriate dosing strategy for the Phase 3 program in kidney transplantation.
